Molecular Characterization of the Onset and Progression of Colitis in Inoculated Interleukin-10 Gene-Deficient Mice: A Role for PPAR𝛼

Table 7

Differentially expressed genes in the colon of Il10 −/− mice compared to C57 mice at 7 and 12 weeks of age.

Gene symbol	Gene name	GenBank accession	Il10^−/− versus C57		Il10^−/− versus C57
			7 weeks of age		12 weeks of age
			FC	FDR	FC	FDR
Actg2	actin, gamma 2, smooth muscle, enteric	NM_007392	−1.3	0.315	−1.6	0.02
Arhgap12	Rho GTPase activating protein 12	NM_029277	−1.1	0.549	−1.5	<0.001
Arhgdib	Rho GDP dissociation inhibitor (GDI) beta	NM_007486	1.1	0.562	2.0	<0.001
Arhgef10L	Rho guanine nucleotide exchange factor (GEF) 10-like	AK028648	2.4	<0.001	2.3	<0.001
Bcl2A1	BCL2-related protein A1	NM_007534	1.6	0.001	2.7	<0.001
Bcl3	B-cell CLL/lymphoma 3	NM_033601	1.6	0.044	1.7	0.015
C1Qa	complement component 1, q subcomponent, A chain	NM_007572	1.1	0.67	1.6	0.003
C1Qc	complement component 1, q subcomponent, C chain	NM_007574	1.3	0.29	1.8	0.005
C1R	complement component 1, r subcomponent	NM_023143	1.5	0.018	2.0	<0.001
C1S	complement component 1, s subcomponent	NM_144938	1.3	0.059	1.9	<0.001
C2	complement component 2	NM_013484	1.2	0.337	2.6	<0.001
C3	complement component 3	NM_009778	1.8	0.015	4.5	<0.001
C4B	complement component 4B (Chido blood group)	NM_009780	−1.0	0.976	1.6	0.005
Ccl5	chemokine (C-C-motif) ligand 5 (Rantes)	NM_013653	1.1	0.7	2.3	<0.001
Cd74	CD74 molecule, major histocompatibility complex, class II invariant chain	NM_010545	4.0	<0.001	5.5	<0.001
Fas	Fas (TNF receptor superfamily, member 6)	NM_007987	1.9	<0.001	1.5	<0.001
Gsn	gelsolin	NM_146120	−1.8	0.006	−2.0	<0.001
Hla-A	major histocompatibility complex, class I, A	NM_010391	1.4	0.201	2.3	<0.001
Hla-B	major histocompatibility complex, class I, B	NM_008199	−1.4	0.104	1.9	<0.001
Hla-C	major histocompatibility complex, class I, C	NM_010380	1.4	0.005	2.3	<0.001
Hla-Dma	major histocompatibility complex, class II, DM alpha	NM_010386	1.5	<0.001	2.1	<0.001
Hla-Dmb	major histocompatibility complex, class II, DM beta	NM_010387	4.9	<0.001	6.6	<0.001
Hla-Dqa1	major histocompatibility complex, class II, DQ alpha 1	NM_010378	1.8	<0.001	2.9	<0.001
Hla-Dqb2	major histocompatibility complex, class II, DQ beta 2	NM_010379	3.1	<0.001	5.3	<0.001
Hla-Drb1	major histocompatibility complex, class II, DR beta 1	NM_010382	2.5	<0.001	4.5	<0.001
Hla-G	major histocompatibility complex, class I, G	NM_013819	1.4	0.013	2.0	<0.001
Hmgcr	3-hydroxy-3-methylglutaryl-Coenzyme A reductase	NM_008255	1.7	0.005	1.5	0.005
Ido1 (Indo)	indoleamine 2,3-dioxygenase 1	NM_008324	6.6	<0.001	8.1	<0.001
Ifng	interferon, gamma	NM_008337	1.4	0.071	1.7	0.003
Il1B	interleukin 1, beta	NM_008361	1.8	0.211	6.4	<0.001
Il1Rn	interleukin 1 receptor antagonist	NM_031167	1.3	0.442	1.8	0.024
Il10	interleukin 10	NM_010548	1.1	0.461	1.1	0.421
Mapk13	mitogen-activated protein kinase 13	NM_011950	1.8	<0.001	1.7	<0.001
Mapk9	mitogen-activated protein kinase 9	NM_016961	1.5	0.004	1.6	<0.001
Nfkbia	nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha	NM_010907	1.6	0.002	1.6	0.001
Nfkbie	nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, epsilon	NM_008690	1.5	0.001	1.7	<0.001
Ppara	peroxisome proliferator-activated receptor alpha	NM_011144	−2.0	<0.001	−1.7	0.001
Ppargc1A	peroxisome proliferator-activated receptor gamma, coactivator 1 alpha	NM_008904	−1.7	0.008	−1.4	0.052
Tlr2	toll-like receptor 2	NM_011905	1.1	0.857	1.9	0.001
Tlr9	toll-like receptor 9	NM_031178	1.9	<0.001	1.9	<0.001
Tnf	tumour necrosis factor (TNF superfamily, member 2)	NM_013693	1.3	0.064	1.7	<0.001
Tnfrsf1B	tumour necrosis factor receptor superfamily, member 1B	NM_011610	1.3	0.115	1.5	0.003
Txn	thioredoxin	NM_011660	−1.2	0.494	−1.0	0.932

Genes were grouped into one or more of the following IPA pathways: antigen presentation, graft versus host disease signaling, allograft rejection signaling, interferon signaling, role of PKR in interferon induction and antiviral response, dendritic cell maturation, complement system, endoplasmic reticulum stress, and steroid metabolism. Genes with fold change (FC) ≥1.5 and false discovery rate (FDR) or 𝑞<0.05 were considered for pathway analysis.